One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
ОЗОН Фармацевтика logo
ОЗОН Фармацевтика OZPH
report update icon

Quarterly report 2026-Q2
added 09-06-2026

ОЗОН Фармацевтика Financial Ratios 2025-2021 | OZPH

Annual Financial Ratios ОЗОН Фармацевтика

2025 2024 2023 2022 2021

Price Earnings Ratio, P/E

10 10 9 10 9

Price Sales Ratio, P/S

2 2 2 2 2

Price To Book Ratio, P/B

3 2 2 2 3

Price Earnings To Growth Ratio, PEG

49 - - - -

Operating Cash Flow Per Share

2.78 5.3 4.66 -0.99 2.77

Free Cash Flow Per Share

-0.26 1 4 -2 1

Cash Per Share

2.43 5.09 0.95 1.11 1.37

Payout Ratio

0.2 0.1 - - -

Dividend Yield

0.02 0.01 - - -

Operating Profit Margin

0.34 0.31 0.31 0.29 0.31

Pretax Profit Margin

0.2 0.18 0.2 0.19 0.22

Net Profit Margin

0.2 0.18 0.2 0.19 0.22

Return On Assets, ROA

0.12 0.09 0.12 0.11 0.13

Return On Equity, ROE

0.19 0.18 0.25 0.25 0.31

Return On Capital Employed, ROCE

0.3 0.23 0.25 0.21 0.26

Net Income Per Ebt

1.0 1.0 1.0 1.0 1.0

Ebt Per Ebit

0.57 0.58 0.65 0.66 0.73

Ebit Per Revenue

0.34 0.31 0.31 0.29 0.31

Debt Ratio

0.55 0.63 0.54 0.58 0.57

Debt Equity Ratio

0.5 0.84 0.59 0.79 0.62

Long Term Debt To Capitalization

0.33 0.46 0.37 0.44 0.38

Total Debt To Capitalization

0.33 0.46 0.37 0.44 0.38

Interest Coverage

2.77 3.2 5.35 5.5 9.54

Cash Flow To Debt Ratio

0.28 0.38 0.5 -0.09 0.35

Company Equity Multiplier

2.24 2.68 2.19 2.37 2.34

Asset Turnover

0.59 0.52 0.57 0.56 0.6

Operating Cash Flow Sales Ratio

0.1 0.23 0.24 -0.05 0.16

Free Cash Flow Operating Cash Flow Ratio

-0.22 0.27 0.85 1.69 0.57

Cash Flow Coverage Ratios

0.28 0.38 0.5 -0.09 0.35

Capital Expenditure Coverage Ratio

0.82 1.36 6.6 -1.46 2.33

Dividend Paid And Capex Coverage Ratio

0.63 1.22 6.6 -1.46 2.33

Dividend Payout Ratio

0.2 0.1 - - -

Price To Free Cash Flows Ratio, P/FCF

-82.33 29.42 8.85 -20.88 22.15

Price To Operating Cash Flows Ratio, P/OCF

18.49 7.82 7.51 -35.21 12.64

Price Cash Flow Ratio, P/CF

18.49 7.82 7.51 -35.21 12.64

Enterprise Value Multiple, EV

6 6 6 7 7

Price Fair Value, P/FV

3 2 2 2 3

All numbers in RUB currency

Multiples are an important financial analysis tool for the company ОЗОН Фармацевтика, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 4.2 -0.71 % $ 651 M usaUSA
AbbVie AbbVie
ABBV
$ 293.87 0.19 % $ 520 B usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 151.6 -3.2 % $ 19.9 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 302.6 -0.19 % $ 23.6 B usaUSA
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
Liquidia Corporation Liquidia Corporation
LQDA
$ 51.37 7.31 % $ 4.42 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 45.05 -9.97 % $ 4.05 B schweizSchweiz
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 48.48 -5.96 % $ 5.56 B usaUSA
Geron Corporation Geron Corporation
GERN
$ 0.96 -3.71 % $ 640 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.8 1.06 % $ 128 B usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
- -3.76 % $ 3.47 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 7.4 -0.13 % $ 113 M australiaAustralia
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 30.68 -1.81 % $ 2.04 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.0 -6.76 % $ 48.8 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 317.26 0.99 % $ 6.14 B usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 432.7 1.47 % $ 1.29 T usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 14.0 -3.06 % $ 16.9 B australiaAustralia
CorMedix CorMedix
CRMD
$ 5.37 -2.1 % $ 387 K usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
MannKind Corporation MannKind Corporation
MNKD
$ 4.22 0.84 % $ 1.29 B usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
MediciNova MediciNova
MNOV
$ 1.4 -4.76 % $ 68.7 M usaUSA
Merck & Co. Merck & Co.
MRK
$ 147.75 -0.68 % $ 370 B usaUSA
Moderna Moderna
MRNA
$ 250.79 -6.77 % $ 97.6 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
$ 11.18 -7.72 % $ 1.21 B usaUSA
Novartis AG Novartis AG
NVS
$ 163.39 -0.18 % $ 317 B schweizSchweiz
Omeros Corporation Omeros Corporation
OMER
$ 17.3 -1.48 % $ 1.1 B usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
$ 3.97 -0.75 % $ 164 M israelIsrael
Tyme Technologies Tyme Technologies
TYME
- 8.07 % $ 54 M usaUSA
Puma Biotechnology Puma Biotechnology
PBYI
$ 8.13 -3.22 % $ 407 M usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
$ 1.02 -5.09 % $ 47.3 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Pfizer Pfizer
PFE
$ 29.34 0.36 % $ 167 B usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
PainReform Ltd. PainReform Ltd.
PRFX
$ 0.78 -4.24 % $ 505 K israelIsrael